Mankind Pharma

Mankind Pharma P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Mankind Pharma (MANKIND.NS) as of Nov 1, 2026 is 34.16. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 35.61 — a change of -4.07% (lower).

P/CF

34.16

YoY

-4.07%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Mankind Pharma is 2026 34.16 . P/CF (Price-to-Cash-Flow Ratio) of Mankind Pharma was 2025 35.61 . It decreases by -4.07% lower compared to the previous year.

The Mankind Pharma P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2019
143.15 INR
Jan 1, 2020
80.35 INR
Jan 1, 2021
75.57 INR
Jan 1, 2022
93.44 INR
Jan 1, 2023
47.40 INR
Jan 1, 2024
39.93 INR
Jan 1, 2025
35.61 INR
Jan 1, 2026
34.16 INR
The Mankind Pharma P/CF history
YEARP/CFYoY
34.16-4.07%
35.61-10.81%
39.93-15.76%
47.40-49.28%
93.44+23.64%
75.57-5.94%
80.35-43.87%
143.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mankind Pharma Stock analysis

What does Mankind Pharma do? Mankind Pharma Ltd develops, manufactures, and markets pharmaceutical formulations across therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, and respiratory treatments. The company's portfolio includes brands such as Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, and Monticop, targeting acute and chronic conditions. These products are sold to healthcare providers, hospitals, and pharmacies across India, serving patients in diverse medical needs. The firm generates revenue through the sale of prescription and over-the-counter pharmaceuticals, leveraging its extensive portfolio in multiple therapeutic segments. Mankind Pharma focuses on therapeutic areas like anti-diabetic, dermatology, gynecology, pain/analgesics, urology, ophthalmology, and antiviral treatments, with brands such as Glimestar for diabetes and Manforce (Rx) for sexual health. The company's consumer healthcare products complement its prescription offerings, expanding market reach. Revenue streams come from the direct sale of branded formulations to distributors and retail chains, with no mention of external partnerships or additional services beyond pharmaceutical manufacturing and marketing. The company's therapeutic portfolio spans anti-malarial, blood-related, hormones, antineoplastic, hepatoprotective, and parenteral treatments, supported by brands like Cefakind for infections and Zenflox for respiratory issues. Sales are driven by its diverse product range covering both prescription and consumer healthcare segments, with no indication of licensing agreements or third-party collaborations. Mankind Pharma's revenue model relies solely on the marketing and distribution of its own branded pharmaceutical products within India's healthcare ecosystem. Mankind Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mankind Pharma stock

P/CF (Price-to-Cash-Flow Ratio) of Mankind Pharma is 34.16 in 2026.

P/CF (Price-to-Cash-Flow Ratio) of Mankind Pharma changed from 35.61 to 34.16, representing a -4.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Mankind Pharma since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Mankind Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Mankind Pharma

All Key Metrics — Mankind Pharma